Research
Hormonal
Emerging antidiabetic medications show impressive antihyperglycemic effects and remarkable weight loss.
Practitioners should consider these new medications for managing T2D due to their dual benefits.
StrongSupportsmedium confidence
the drugs in the diabetes pipeline are even more promising because of their impressive antihyperglycemic effects coupled with remarkable weight loss.
Why this rating
The abstract discusses the development of new medications, indicating a strong basis for the claims.
Source
New Horizons: Emerging Antidiabetic Medications
Geltrude Mingrone et al. · The Journal of Clinical Endocrinology & Metabolism · 2022
DOI 10.1210/clinem/dgac499
reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →